Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 538

1.

Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.

Rani A, Stebbing J, Giamas G, Murphy J.

Front Endocrinol (Lausanne). 2019 May 24;10:245. doi: 10.3389/fendo.2019.00245. eCollection 2019. Review.

2.

Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.

Stebbing J, Singh Wasan H.

J Clin Oncol. 2019 Jun 7:JCO1901185. doi: 10.1200/JCO.19.01185. [Epub ahead of print] No abstract available.

PMID:
31173553
3.

SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors.

Pfeifer M, Brem R, Lippert TP, Boulianne B, Ho HN, Robinson ME, Stebbing J, Feldhahn N.

J Immunol. 2019 Jun 15;202(12):3423-3433. doi: 10.4049/jimmunol.1801618. Epub 2019 May 13.

4.

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA.

Clin Cancer Res. 2019 Apr 16. doi: 10.1158/1078-0432.CCR-18-3663. [Epub ahead of print]

PMID:
30992300
5.

Ginseng Berry Extract Rich in Phenolic Compounds Attenuates Oxidative Stress but not Cardiac Remodeling post Myocardial Infarction.

Parikh M, Raj P, Yu L, Stebbing JA, Prashar S, Petkau JC, Tappia PS, Pierce GN, Siow YL, Brown D, Blewett H, Netticadan T.

Int J Mol Sci. 2019 Feb 24;20(4). pii: E983. doi: 10.3390/ijms20040983. Erratum in: Int J Mol Sci. 2019 Apr 09;20(7):.

6.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
7.

Factors affecting adenoma detection rate in a national flexible sigmoidoscopy screening programme: a retrospective analysis.

Bevan R, Blanks RG, Nickerson C, Saunders BP, Stebbing J, Tighe R, Veitch AM, Garrett W, Rees CJ.

Lancet Gastroenterol Hepatol. 2019 Mar;4(3):239-247. doi: 10.1016/S2468-1253(18)30387-X. Epub 2019 Jan 15.

PMID:
30655218
8.

Endoscopy in 2017: a national survey of practice in the UK.

Shenbagaraj L, Thomas-Gibson S, Stebbing J, Broughton R, Dron M, Johnston D, Shaw T, Haboubi HN, Green JT.

Frontline Gastroenterol. 2019 Jan;10(1):7-15. doi: 10.1136/flgastro-2018-100970. Epub 2018 Apr 24.

PMID:
30651952
9.

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Huang Q, Zhang H, Hai J, Socinski MA, Lim E, Chen H, Stebbing J.

Oncoimmunology. 2018 Jun 20;7(12):e1396403. doi: 10.1080/2162402X.2017.1396403. eCollection 2018.

PMID:
30524878
10.

The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention.

Renziehausen A, Wang H, Rao B, Weir L, Nigro CL, Lattanzio L, Merlano M, Vega-Rioja A, Del Carmen Fernandez-Carranco M, Hajji N, Matin R, Harwood C, Li S, Sim VR, O'Neill K, Evans A, Thompson A, Szlosarek P, Fleming C, Stebbing J, Proby C, Tzakos AG, Syed N, Crook T.

Oncogene. 2019 Mar;38(13):2320-2336. doi: 10.1038/s41388-018-0563-y. Epub 2018 Nov 26.

PMID:
30478450
11.

Human NK Cells Develop an Exhaustion Phenotype During Polar Degranulation at the Aspergillus fumigatus Hyphal Synapse.

Santiago V, Rezvani K, Sekine T, Stebbing J, Kelleher P, Armstrong-James D.

Front Immunol. 2018 Oct 22;9:2344. doi: 10.3389/fimmu.2018.02344. eCollection 2018.

12.

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.

Simon T, Pinioti S, Schellenberger P, Rajeeve V, Wendler F, Cutillas PR, King A, Stebbing J, Giamas G.

Mol Cancer. 2018 Aug 31;17(1):132. doi: 10.1186/s12943-018-0878-x.

13.

Gene editing in the context of an increasingly complex genome.

Blighe K, DeDionisio L, Christie KA, Chawes B, Shareef S, Kakouli-Duarte T, Chao-Shern C, Harding V, Kelly RS, Castellano L, Stebbing J, Lasky-Su JA, Nesbit MA, Moore CBT.

BMC Genomics. 2018 Aug 8;19(1):595. doi: 10.1186/s12864-018-4963-8. Review.

14.

Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma.

Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H.

J Gastrointest Oncol. 2018 Apr;9(2):275-281. doi: 10.21037/jgo.2018.01.14.

15.

TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x.

16.

Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.

Centelles MN, Wright M, So PW, Amrahli M, Xu XY, Stebbing J, Miller AD, Gedroyc W, Thanou M.

J Control Release. 2018 Jun 28;280:87-98. doi: 10.1016/j.jconrel.2018.04.047. Epub 2018 May 1.

PMID:
29723616
17.

Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.

Frampton AE, Prado MM, López-Jiménez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, Giovannetti E, Habib NA, Castellano L, Stebbing J, Krell J, Jiao LR.

Oncotarget. 2018 Apr 10;9(27):19006-19013. doi: 10.18632/oncotarget.24873. eCollection 2018 Apr 10.

18.

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Moderau N, Poyia F, Schwartzberg LS, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Feb 24;9(25):17589-17596. doi: 10.18632/oncotarget.24564. eCollection 2018 Apr 3.

19.

Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas.

Begum S, Yiu A, Stebbing J, Castellano L.

Oncogene. 2018 Jul;37(30):4055-4057. doi: 10.1038/s41388-018-0230-3. Epub 2018 Apr 30.

PMID:
29706655
20.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
21.

Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Herzog T, Levitan J, Moderau N, Schwartzberg L, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15166. doi: 10.18632/oncotarget.24691. eCollection 2018 Mar 13.

22.

Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Carter P, Alifrangis C, Chandrasinghe P, Cereser B, Del Bel Belluz L, Leo CA, Moderau N, Tabassum N, Warusavitarne J, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15165. doi: 10.18632/oncotarget.24690. eCollection 2018 Mar 13.

23.

Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15164. doi: 10.18632/oncotarget.24689. eCollection 2018 Mar 13.

24.

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.

Stebbing J, Baranau Y, Manikhas A, Lee SJ, Thiruchelvam P, Leff D, Esteva FJ.

Expert Rev Anticancer Ther. 2018 Jun;18(6):531-541. doi: 10.1080/14737140.2018.1457442. Epub 2018 Apr 2. Review.

PMID:
29580109
25.

Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.

Tzoulis P, Corbett RW, Ponnampalam S, Baker E, Heaton D, Doulgeraki T, Stebbing J.

Endocrinol Diabetes Metab Case Rep. 2018 Mar 21;2018. pii: 18-0111. doi: 10.1530/EDM-18-0111. eCollection 2018.

26.

Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.

Pannuti A, Filipovic A, Hicks C, Lefkowitz E, Ptacek T, Stebbing J, Miele L.

PLoS One. 2018 Mar 23;13(3):e0194790. doi: 10.1371/journal.pone.0194790. eCollection 2018.

27.

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments.

Alifrangis C, Carter P, Cereser B, Chandrasinghe P, Belluz LDB, Lim E, Moderau N, Poyia F, Tabassum N, Zhang H, Krell J, Stebbing J.

Oncotarget. 2018 Feb 1;9(16):12805-12811. doi: 10.18632/oncotarget.24375. eCollection 2018 Feb 27.

28.

The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Carter P, Alifrangis C, Chandrasinghe P, Cereser B, Del Bel Belluz L, Leo CA, Moderau N, Tabassum N, Warusavitarne J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(13):11371-11376. doi: 10.18632/oncotarget.24257. eCollection 2018 Feb 16. Erratum in: Oncotarget. 2018 Mar 13;9(19):15165.

29.

LMTK3 confers chemo-resistance in breast cancer.

Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, Wendler F, Simon T, Szabó KS, O'Hanlon T, Dean M, Roslani AC, Cheah SH, Lee SC, Giamas G.

Oncogene. 2018 Jun;37(23):3113-3130. doi: 10.1038/s41388-018-0197-0. Epub 2018 Mar 15.

30.

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Belluz LDB, Herzog T, Levitan J, Moderau N, Schwartzberg L, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(10):9456-9467. doi: 10.18632/oncotarget.24258. eCollection 2018 Feb 6. Erratum in: Oncotarget. 2018 Mar 13;9(19):15166.

31.

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

Esteva FJ, Saeki T, Kim H, Stebbing J.

Future Oncol. 2018 Aug;14(19):1909-1919. doi: 10.2217/fon-2017-0679. Epub 2018 Feb 27. Review.

PMID:
29482364
32.

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19. Erratum in: Oncotarget. 2018 Mar 13;9(19):15164.

33.

Targeted cancer therapies: Oral health care implications.

Georgakopoulou E, Stebbing J, Scully C.

J Am Dent Assoc. 2018 Feb;149(2):100-111. doi: 10.1016/j.adaj.2017.08.046.

PMID:
29389333
34.

Harms of cigarette smoking: call to increase knowledge among children.

Lonergan B, Harding V, Cohen H, Wylleman E, Cohen R, Stebbing J.

Eur J Cancer Prev. 2019 Jan;28(1):54-57. doi: 10.1097/CEJ.0000000000000409.

35.

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.

Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):505-514. doi: 10.1007/s00280-017-3510-7. Epub 2018 Jan 12.

36.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation.

Soraas L, Stebbing J.

J Thorac Oncol. 2018 Mar;13(3):454-458. doi: 10.1016/j.jtho.2017.11.128. Epub 2017 Dec 13.

37.

Thirty years of Oncogene.

Miller G, Stebbing J.

Oncogene. 2018 Feb 1;37(5):553-554. doi: 10.1038/onc.2017.388. Epub 2017 Oct 23. No abstract available.

38.

The importance of being earnest in post-publication review: scientific fraud and the scourges of anonymity and excuses.

Stebbing J, Sanders DA.

Oncogene. 2018 Feb 8;37(6):695-696. doi: 10.1038/onc.2017.390. Epub 2017 Oct 16. No abstract available.

39.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

40.

Liquorice: a treatment for all sorts?

Harding V, Stebbing J.

Lancet Oncol. 2017 Sep;18(9):1155. doi: 10.1016/S1470-2045(17)30628-9. No abstract available.

41.

Role of SMAD proteins in colitis-associated cancer: from known to the unknown.

Chandrasinghe P, Cereser B, Moorghen M, Al Bakir I, Tabassum N, Hart A, Stebbing J, Warusavitarne J.

Oncogene. 2018 Jan 4;37(1):1-7. doi: 10.1038/onc.2017.300. Epub 2017 Sep 4. Review.

42.

The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.

Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, Vaughan S, El-Bahrawy M, Stebbing J, Recchi C, Gabra H.

Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.

43.

Chilli-too hot to handle?

Craddock C, Cathcart P, Stebbing J.

Lancet Oncol. 2017 Aug;18(8):1005. doi: 10.1016/S1470-2045(17)30522-3. Epub 2017 Jul 26. No abstract available.

44.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

45.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ.

Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433. Lancet Oncol. 2017 Sep;18(9):e510.

46.

Fasting: starving cancer.

Cathcart P, Craddock C, Stebbing J.

Lancet Oncol. 2017 Apr;18(4):431. doi: 10.1016/S1470-2045(17)30196-1. No abstract available.

47.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

48.

The relationship between ethnicity, social deprivation and late presentation of colorectal cancer.

Askari A, Nachiappan S, Currie A, Latchford A, Stebbing J, Bottle A, Athanasiou T, Faiz O.

Cancer Epidemiol. 2017 Apr;47:88-93. doi: 10.1016/j.canep.2017.01.007. Epub 2017 Feb 4.

PMID:
28167416
49.

Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.

Castellano L, Dabrowska A, Pellegrino L, Ottaviani S, Cathcart P, Frampton AE, Krell J, Stebbing J.

Nucleic Acids Res. 2017 May 5;45(8):4401-4412. doi: 10.1093/nar/gkx022.

50.

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.

Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, Goddard K, Shahin V, Woodley-Barker L, Rosales BM, Coombes RC, Stebbing J, Shaw JA.

Clin Chem. 2017 Feb;63(2):532-541. doi: 10.1373/clinchem.2016.261834. Epub 2016 Dec 9.

Supplemental Content

Loading ...
Support Center